<SEC-DOCUMENT>0001140361-23-023203.txt : 20230505
<SEC-HEADER>0001140361-23-023203.hdr.sgml : 20230505
<ACCEPTANCE-DATETIME>20230505160652
ACCESSION NUMBER:		0001140361-23-023203
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230505
DATE AS OF CHANGE:		20230505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		23893813

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>brhc20052574_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr align="center" style="border-width: 4px medium 1px; border-style: solid none; border-color: black currentColor; border-image: none; height: 10px; text-align: center; color: rgb(255, 255, 255); margin-right: auto; margin-left: auto; background-color: rgb(255, 255, 255);">
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>
      <div>
        <div><br>
        </div>
        <div>
          <hr noshade="noshade" align="center" style="border: currentColor; border-image: none; height: 2px; text-align: center; color: rgb(0, 0, 0); margin-right: auto; margin-left: auto; background-color: rgb(0, 0, 0);">
          <div><br>
          </div>
        </div>
      </div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 8-K</div>
      <div style="text-align: center;"><br>
        </div>
      <hr noshade="noshade" align="center" style="border: currentColor; border-image: none; height: 2px; text-align: center; color: rgb(0, 0, 0); margin-right: auto; margin-left: auto; background-color: rgb(0, 0, 0);">
      <div style="text-align: center;"><br>
      </div>
      <div style="text-align: center;">&#160;<font style="font-weight: bold;">CURRENT REPORT</font></div>
      <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>
      <div style="text-align: center;"><br>
        </div>
      <div style="text-align: center;">Date of report (Date of earliest event reported): <font style="font-weight: bold;">May 2, 2023</font></div>
      <div style="text-align: center;"><br>
        </div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">Catalyst Biosciences, Inc.<br>
      </div>
      <div style="text-align: center;">(Exact Name of Registrant as Specified in Charter)</div>
      <div><br>
        </div>
      <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse;" id="z62a901b699e147bfb2ca27a16ba2aa50">

          <tr>
            <td style="width: 33.33%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Delaware<br>
              </div>
            </td>
            <td style="width: 34%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">000-51173<br>
              </div>
            </td>
            <td style="width: 33.34%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">56-2020050<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 33.33%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">(State or Other Jurisdiction of Incorporation)</div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">(Commission File Number)</div>
            </td>
            <td style="width: 33.34%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">(IRS Employer Identification No.)</div>
            </td>
          </tr>

      </table>
      <div><br>
        </div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse;" id="zdce22a5440224892bcfb8369ffaf55c4">

          <tr>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">611 Gateway Blvd<br>
              </div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Suite 120<br>
              </div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">South San Francisco, CA</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">94080<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">(Address of Principal Executive Offices)</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">(Zip Code)</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center;"><br>
        </div>
      <div style="text-align: center;">Registrant&#8217;s telephone number, including area code: <font style="font-weight: bold;">(650) 871-0761</font></div>
      <div style="text-align: center;">&#160;<font style="font-weight: bold;">Not Applicable</font></div>
      <div style="text-align: center;">(Former Name or Former Address, if Changed Since Last Report)</div>
      <div><br>
        <hr noshade="noshade" align="center" style="border: currentColor; border-image: none; height: 2px; text-align: center; color: rgb(0, 0, 0); margin-right: auto; margin-left: auto; background-color: rgb(0, 0, 0);">
        <div><br>
        </div>
      </div>
      <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions (<font style="font-style: italic;">see</font> General Instruction A.2. below):</div>
      <div><br>
        </div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="z7424e3f233cc4fa0bcbc165278e71160" class="DSPFListTable">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#9744;<br>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>
          </tr>

      </table>
      <div><br>
        </div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="z7c8f0837f795418cb69ae4f37cf6c2dc" class="DSPFListTable">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#9746;<br>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>
          </tr>

      </table>
      <div><br>
        </div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="z12fac7aa146e4f71a6e0e56e32b7c052" class="DSPFListTable">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#9744;<br>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>
          </tr>

      </table>
      <div><br>
        </div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="z8ea02d9848954073930f58aba0970542" class="DSPFListTable">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#9744;<br>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>
          </tr>

      </table>
      <div><br>
        </div>
      <div>
        <div>Securities registered pursuant to Section 12(b) of the Act:</div>
      </div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse;" id="z2b4492731cfc4fccb62c6fed78d45357">

          <tr>
            <td nowrap="nowrap" style="width: 33.99%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2px; border-bottom-style: solid;">
              <div style="text-align: center;">&#160;<font style="color: rgb(0, 0, 0);">Title of each class</font></div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 30%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2px; border-bottom-style: solid;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Trading Symbol(s)</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 32%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2px; border-bottom-style: solid;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Name of each exchange on which</div>
              <div style="text-align: center; color: rgb(0, 0, 0);">registered</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33.99%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Common Stock<br>
              </div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">CBIO<br>
              </div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">The Nasdaq Capital Market<br>
              </div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or
        Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>
      <div><br>
        </div>
      <div style="text-indent: 36pt;">Emerging growth company &#9744;</div>
      <div><br>
        </div>
      <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
        revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>
      <div><br>
        </div>
      <div>
        <hr align="center" style="border-width: 1px medium 4px; border-style: solid none; border-color: black currentColor; border-image: none; height: 10px; text-align: center; color: rgb(255, 255, 255); margin-right: auto; margin-left: auto; background-color: rgb(255, 255, 255);"></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); clear: both; background-color: rgb(0, 0, 0);"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" id="za7a8e88e2c1e4a3badc8b5d5e2f0fe58" class="DSPFListTable">

          <tr>
            <td style="width: 72pt; font-weight: bold; vertical-align: top;">Item 3.01</td>
            <td style="width: auto; text-align: justify; vertical-align: top;">
              <div style="font-weight: bold;">Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify;">As previously reported, on November 2, 2022, Catalyst Biosciences, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;Catalyst&#8221;), received a letter from the
        Listing Qualifications Department of The Nasdaq Stock Market, LLC (&#8220;Nasdaq&#8221;) informing the Company that, because the closing bid price for the Company&#8217;s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company was
        not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;). The Company was granted 180 calendar days, or
        until May 1, 2023, to regain compliance with the Minimum Bid Price Requirement.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">On May 2, 2023, the Company was notified by the Listing Qualifications Staff (the &#8220;Staff&#8221;) of Nasdaq that the Company did not meet the Minimum Bid Price
        Requirement and was not eligible for a second 180-day period. As previously reported, on April 4, 2023, the Staff notified the Company that it failed to comply with Nasdaq&#8217;s $2,500,000 minimum stockholders&#8217; equity requirement for continued listing
        as set forth in Listing Rule 5550(b)(1) (the &#8220;Equity Requirement&#8221;). The deficiency with regards to the Equity Requirement serves as an additional and separate basis for delisting. The Company plans to timely submit a hearing request to Nasdaq&#8217;s
        Hearings Department. A hearing request will stay the suspension of the Company&#8217;s common stock pending the panel&#8217;s conclusion of the hearing process. The Company believes that completion of the pending Business Combination Transaction (as defined
        below) and reverse stock split as described in the preliminary proxy statement (the &#8220;Preliminary Proxy Statement&#8221;) filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 30, 2023 will enable the combined company following the
        Business Combination Transaction to meet the applicable Nasdaq initial listing requirements, providing a basis for suspension of delisting. There can be no assurance that the Company will succeed in its hearing and that the panel will grant the
        Company&#8217;s request for a suspension of delisting or continued listing on The Nasdaq Capital Market, or that the combined company will meet Nasdaq&#8217;s initial listing requirements.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">Forward-Looking Statements</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning
        of the Private Securities Litigation Reform Act of 1995. Such statements include Catalyst&#8217;s plans to submit a plan to Nasdaq to regain compliance with Nasdaq listing requirements, its intent to pursue a hearing before the Nasdaq Hearings Panel, and
        the potential that Catalyst will regain compliance. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more
        fully in the Company&#8217;s filings with the Securities and Exchange Commission, including, without limitation, the Company&#8217;s most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange
        Commission. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances
        that exist after the date on which they were made.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">No Offer or Solicitation</div>
      <div><br>
      </div>
      <div style="text-align: justify;">This Current Report on Form 8-K is not intended to be, and does not constitute, an offer to sell or the solicitation of an offer to subscribe for or buy or
        an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in
        contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended. Subject to certain exceptions to be approved by the relevant regulators or
        certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or
        instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); clear: both; background-color: rgb(0, 0, 0);"></div>
      </div>
      <div style="text-align: justify; font-weight: bold;">Important Additional Information Will be Filed with the SEC</div>
      <div><br>
      </div>
      <div style="text-align: justify;">In connection with the proposed transactions between Catalyst, GNI USA, Inc., a Delaware corporation (&#8220;GNI USA&#8221;), GNI Group Ltd., a company incorporated
        under the laws of Japan with limited liability (&#8220;GNI Group&#8221;), GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (&#8220;GNI HK&#8221;), Shanghai Genomics, Inc., a company organized under the laws of the People&#8217;s
        Republic of China (&#8220;Shanghai Genomics&#8221;, and collectively with GNI USA, GNI Group and GNI HK, the &#8220;Contributors,&#8221; and each a &#8220;Contributor&#8221;), the individuals (each, a &#8220;Minority Holder&#8221; and collectively, the &#8220;Minority Holders&#8221;) listed on Annex A of
        that certain Business Combination Agreement, dated December 26, 2022, and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (the &#8220;CPI&#8221;) (the &#8220;Business Combination Transaction&#8221;), Catalyst has filed relevant materials with
        the SEC, including a Preliminary Proxy Statement, and intends to file a definitive proxy statement and a registration statement on Form S-3 that will contain a prospectus of Catalyst. CATALYST URGES ITS INVESTORS AND STOCKHOLDERS TO READ THESE
        MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CATALYST, CPI, THE PROPOSED TRANSACTIONS AND RELATED MATTERS. Investors and stockholders may obtain free copies of the
        Preliminary Proxy Statement, and will be able to obtain free copies of the definitive proxy statement and the prospectus and other documents filed by Catalyst with the SEC (when they become available), through the website maintained by the SEC at
        www.sec.gov. In addition, investors and stockholders will be able to obtain free copies of the definitive proxy statement and prospectus and other documents filed by Catalyst with the SEC by contacting Catalyst Biosciences, Inc. at 611 Gateway
        Blvd. Suite 120, South San Francisco, California 94080. Investors and stockholders are urged to read the definitive proxy statement and prospectus and the other relevant materials when they become available before making any voting or investment
        decision with respect to the proposed transactions. </div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">Participants in the Solicitation</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Catalyst, the Contributors, the Minority Holders, the entities held by the Minority Holders, and CPI, and their respective directors and executive officers
        may be considered participants in the solicitation of proxies in connection with the proposed transactions. Information about Catalyst&#8217;s directors and executive officers is included in Catalyst&#8217;s most recent Annual Report on Form 10-K, including
        any information incorporated therein by reference, as filed with the SEC, the&#160; Preliminary Proxy Statement for Catalyst&#8217;s 2023 special meeting of stockholders filed with the SEC on March 30, 2023, and Catalyst&#8217;s Form 8-K filed with the SEC on
        December 27, 2022. Information regarding the persons who may be deemed participants in the solicitation of proxies has been included in the Preliminary Proxy Statement filed with the SEC and additional information may be included in the definitive
        proxy statement and prospectus relating to the proposed transactions to be filed with the SEC. These documents can be obtained free of charge from the sources indicated above.</div>
      <br>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); clear: both; background-color: rgb(0, 0, 0);"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div><br>
        </div>
      <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
        the undersigned hereunto duly authorized.</div>
      <div><br>
        </div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse;" id="zb6485f218f304c25b98e6fb481c78e88">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="width: 50%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">CATALYST BIOSCIENCES, INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Date: May 5, 2023</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2px; border-bottom-style: solid;">
              <div style="color: rgb(0, 0, 0);">/s/ Nassim Usman, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 3%; vertical-align: top;"><br>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Nassim Usman, Ph.D.</div>
              <div style="color: rgb(0, 0, 0);">President and Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="border: currentColor; border-image: none; height: 2px; text-align: center; color: rgb(0, 0, 0); margin-right: auto; margin-left: auto; background-color: rgb(0, 0, 0);"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
